Alla studier
RekryteringFAS3INTERVENTIONELL

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

This research study is testing a new medication called Eloralintide (also known as LY3841136). It's designed for adults who are overweight or have obesity but do not have type 2 diabetes. The main goal is to find out if Eloralintide can effectively help people manage their weight and if it's safe to use. Some people will receive Eloralintide, while others will receive a placebo (a dummy treatment). The study has two parts: a main phase lasting about 75 weeks, and an extended phase for those with prediabetes, which will continue for another two years. This helps researchers understand the longer-term effects of the medication.

Överblick

Status
Rekrytering
Fas
FAS3
Sponsor
Eli Lilly och Company
Inskrivningsmål
1,980
Starta
06 Feb 2026
Beräknad slutförande
01 Jul 2030

Vad handlar denna studie om?

This study is designed to investigate a new medication called Eloralintide. It's for adults who are overweight or have obesity and are looking for help with weight management, but importantly, they mustn't have type 2 diabetes. The scientists running this study want to learn two main things: first, how well Eloralintide works to help people lose weight, and second, if it's safe to use.

To do this, some people in the study will be given Eloralintide, while others will receive a placebo. A placebo looks just like the study drug but doesn't contain any active medicine. This comparison is important because it helps researchers understand if any changes are truly due to the Eloralintide or if they might have happened anyway. The study is divided into a main phase and an extension phase to get a full picture of the medication's effects.

Finding new ways to manage weight is important for many people, as being overweight or having obesity can sometimes lead to other health problems. This research could help us understand if Eloralintide could be a new option for individuals in the future.

Viktiga punkter

  • Tests a new weight-loss medication called Eloralintide.
  • For adults who are overweight or have obesity, but without type 2 diabetes.
  • Compares Eloralintide against a placebo (dummy treatment).
  • Study lasts about 75 weeks, with an optional extension for some.
  • Aims to check both how well it works and if it's safe.
  • Regular health checks throughout your participation.

Vem kan vara berättigad?

To join this study, you need to be an adult (18 or older) and fit certain health measurements. For instance, your Body Mass Index (BMI) needs to be 30 or higher. If your BMI is 27 or higher, you could also qualify if you have one of these weight-related health conditions: high blood pressure, unhealthy cholesterol levels, sleep apnea (where you stop breathing briefly during sleep), or heart disease. You also need to have tried to lose weight with diet changes before and your weight must have been stable for the three months leading up to the study.

However, some things would mean you can't take part. This includes having had or planning to have weight-loss surgery (like liposuction is okay if it was over a year ago). Similarly, if you've had certain procedures inside your gut for weight loss, you might not be eligible. You also can't have type 1 or type 2 diabetes. If you've had a recent heart attack, stroke, or other serious heart problems in the last three months, or severe heart failure, you won't be able to join. Finally, if you've used other weight-loss medications or remedies in the last three months, you won't qualify.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. Är du 18 år eller äldre?
  2. Is your Body Mass Index (BMI) 30 or higher, or 27 or higher with conditions like high blood pressure or sleep apnea?
  3. Have you tried to lose weight through dieting before?
  4. Have you had stable weight for the past 3 months?
  5. Do you NOT have type 1 or type 2 diabetes?
  6. Have you NOT had any major heart problems (like a heart attack or stroke) in the past 3 months?
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

If you decide to take part in this study, you'll be involved for about 75 weeks, which is roughly a year and a half. During this time, you'll have regular visits to the study clinic where doctors and nurses will check your health, measure your weight, and ask about your well-being. You'll be given either the study medication (Eloralintide) or a placebo, which you'll need to take as instructed.

For some participants who have 'prediabetes' (meaning their blood sugar levels are higher than normal but not yet at the level of type 2 diabetes), the study will continue for an extra two years after the main phase finishes. This 'extension phase' will help researchers understand the long-term effects of the medication in this specific group. Throughout the study, you'll be actively monitored, and you'll have scheduled appointments to ensure your safety and to track your progress.

Potentiella risker och fördelar

Taking part in any medical study has potential benefits and risks. A potential benefit of joining this study could be receiving a new medication that might help you manage your weight. You’ll also receive regular medical check-ups and monitoring by a healthcare team. However, there are potential risks, such as experiencing side effects from the study medication, though these are carefully monitored. It's also possible that the medication might not work for you, or that you could receive the placebo. Your health and safety are paramount, and you are free to withdraw from the study at any time, for any reason, without affecting your usual medical care.

Locations (158)

  • MFA Clinical Research
    Verifierat postnummer
    Tuscaloosa, United States· Rekrytering
  • Headlands Research - Scottsdale
    Verifierat postnummer
    Scottsdale, USA· Rekrytering
  • Neighborhood Healthcare Institute of Health
    Verifierat postnummer
    Escondido, United States· Rekrytering
  • Ark Clinical Research - Fountain Valley
    Verifierat postnummer
    Fountain Valley, United States· Rekrytering
  • Desert Oasis Healthcare Medical Group
    Verifierat postnummer
    Palm Springs, USA· Rekrytering
  • Peninsula Research Associates
    Verifierat postnummer
    Rolling Hills Estates, United States· Rekrytering
  • Care Access - Sacramento
    Verifierat postnummer
    Sacramento, USA· Rekrytering
  • Southern California Clinical Research
    Verifierat postnummer
    Santa Ana, USA· Rekrytering
  • University Clinical Investigators, Inc.
    Verifierat postnummer
    Tustin, USA· Rekrytering
  • Chase Medical Research, LLC
    Verifierat postnummer
    Waterbury, USA· Rekrytering
  • JEM Research Institute
    Verifierat postnummer
    Atlantis, USA· Rekrytering
  • BioMed Research & Medical Center
    Verifierat postnummer
    Miami, USA· Rekrytering

Vanliga frågor

What is Eloralintide?

Eloralintide is a new medication being tested in this study to see if it can help adults who are overweight or have obesity manage their weight.

Vad är en 'placebo'?

A placebo is a 'dummy' treatment that looks just like the real medication but contains no active ingredients. It's used so researchers can compare its effects to the actual drug.

Hur länge kommer studien att pågå om jag deltar?

The main part of the study will last about 75 weeks (around 1.5 years). If you have prediabetes, you might continue for another 2 years in an extension phase.

Can I join if I have diabetes?

No, this study is specifically for people who do not have type 1 or type 2 diabetes.

Will I know if I'm getting the real medication or the placebo?

No, during the study, neither you nor your study doctor will know whether you are receiving Eloralintide or the placebo. This is to ensure fair and unbiased results.

Hur du får reda på mer

Trial question or participation questions: 1-877-CTLILLY (1-877-285-4559) or

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Intresserad av att delta?

Registrera ditt intresse

Dela dina uppgifter och forskarteamet för "A Study of Eloralintide (LY3841136) in Participants With Obe…" kommer att kontakta dig om du kan vara berättigad. Prata alltid med din läkare innan du går med på att delta.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.